SpikImm receives a major funding to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-CoV-2

SpikImm, a biotech company founded in 2021 by Truffle Capital in collaboration with the Institut Pasteur, has been awarded a €15 million non-dilutive financing from the French governmentFrance  2030 program for its "PROPHYMAB" project, which is supported as part of the "Emerging Infectious Diseases and CBRN Threats" Acceleration Strategy.

Find out more